The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 22 February 2005, www.theannals.com, DOI 10.1345/aph.1E365.
 The Annals of Pharmacotherapy: Vol. 39, No. 4, pp. 732-735. DOI 10.1345/aph.1E365
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Villeneuve, E.
Right arrow Articles by Sunderji, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Villeneuve, E.
Right arrow Articles by Sunderji, R.

DRUG INFORMATION ROUNDS

OBJETIVO: Determinar si los inhibidores de glycoproteína (GPI) IIb/IIIa, son efectivos y seguros como terapia adyuvante en intervenciones coronarias percutáneas (PCI), y en pacientes con fallo renal terminal.

FUENTES DE DATOS: Se identificaron artículos de la literatura científica mediante la utilización de las bases de datos de MEDLINE para el período comprendido entre 1966–junio 2004, EMBASE (1980–junio 2004), IPA (1970–junio 2004), y la búsqueda bibliográfica manual.

SÍNTESIS DE DATOS: Aunque la utilidad de los GPI está claramente establecida en las PCI, poco se conoce sobre su uso en pacientes con fallo renal terminal. En base a la escasa información disponible de los registros y de la revisión retrospectiva de los récords de los pacientes, se hace difícil llegar a unas conclusiones definitivas acerca de la utilidad de los GPI en pacientes con fallo renal terminal. La decisión de utilizar abciximab, uno de los agentes de esta clase en pacientes con fallo renal terminal depende de la evaluación individual de cada paciente.

CONCLUSIONES: Se necesita la realización de estudios para evaluar los riesgos versus los beneficios de utilizar los GPI en pacientes con fallo renal terminal.

www.theannals.com, DOI 10.1345/aph.1E365


This article has been cited by other articles:


Home page
 CJASNHome page
M. Mrkobrada, H. Thiessen-Philbrook, R. B. Haynes, A. V. Iansavichus, F. Rehman, and A. X. Garg
Need for Quality Improvement in Renal Systematic Reviews
Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1102 - 1114.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
A S. Mathis and J. J Gugger
Percutaneous Coronary Intervention-Related Bleeding Risk Factors in Current Practice
Ann. Pharmacother., October 1, 2005; 39(10): 1627 - 1632.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Villeneuve, E.
Right arrow Articles by Sunderji, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Villeneuve, E.
Right arrow Articles by Sunderji, R.

homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.